Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05156281 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
A Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,011
- Enrollment target
- 20
- Study locations
NCT05156281: Active Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
NCT05156281 is a Phase 3 study of Relapsing Multiple Sclerosis that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 1,011 participants, below the 2,125-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05156281, a Phase 3 study of Relapsing Multiple Sclerosis, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,011 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Primary Outcome
ARR is the average number of confirmed MS relapses in a year
Conditions Studied
Interventions
- DRUG Teriflunomide
- DRUG Remibrutinib
Study Locations (20)
Florida
- Nova Clinical Research LLC - Bradenton
- University of Florida - Gainesville
- Memorial Healthcare System - Hollywood
- Mayo Clinic Jacksonville - Jacksonville
- Neurology Associates PA - Maitland
- Gables Neurology - Miami
- UM Department Of Neurology - Miami
- Aqualane Clinical Research - Naples
- Advent Health Orlando - Orlando
- Humanity Clinical Research - Pembroke Pines
- Emerald Coast Neurology - Pensacola
California
- Vladimir Royter MD APMC - Hanford
- VA Greater LA Healthcare System - Los Angeles
- Regina Berkovich MD PhD Inc - West Hollywood
Colorado
- CU Anschutz Med Campus - Aurora
- Colorado Neurological Research PC - Denver
District of Columbia
- Georgetown University Hospital Research - Washington D.C.
- Georgetown University Hospital - Washington D.C.
Arizona
- Ctr for Neurology and Spine - Phoenix
Connecticut
- New England Institute for Clinical Research - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,011 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2030-10-30 |
| Phase | Phase 3 |
What the registry record for NCT05156281 still lists
NCT05156281 is an interventional study that assigns participants to a tested intervention. Its 1,011 participants enrollment target places it among the larger protocols in the corpus, below the 2,125-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Teriflunomide is the first listed.
NCT05156281 names 20 study sites across 6 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05156281 about?
NCT05156281 is a clinical study titled "Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)". To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
What is the current status of trial NCT05156281?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,011 participants. The study started on 2021-12-13. Estimated completion is 2030-10-30.
What conditions does trial NCT05156281 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT05156281?
The interventions under investigation include: Teriflunomide (DRUG), Remibrutinib (DRUG).
Who is sponsoring clinical trial NCT05156281?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05156281 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05156281's enrollment target sits among peer trials
1,011 6th of 23 higher than 18 of 23 other Relapsing Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
RECRUITING · Phase 3
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI